Core Viewpoint - Thermo Fisher Scientific Inc. reported strong fourth-quarter results for 2025, exceeding earnings and sales expectations, indicating robust operational performance and strategic growth initiatives [1][2]. Financial Performance - Adjusted earnings for Q4 2025 were $6.57 per share, surpassing the consensus estimate of $6.45 [1]. - Quarterly sales reached $12.22 billion, a 7% increase year-over-year, exceeding the analyst consensus of $11.95 billion [1]. - Organic revenue growth was reported at 3% [1]. Segment Performance - Life Sciences Solutions sales increased by 13.1% to $2.95 billion [3]. - Analytical Instruments sales rose by 1.3% to $2.22 billion [3]. - Specialty Diagnostics revenues reached $1.22 billion, up 5.4% [3]. - Laboratory Products and Biopharma Services sales increased by 7.5% to $6.38 billion [3]. Future Guidance - For 2026, the company projects revenue growth between 4% and 6%, with expected revenue of $46.3 billion to $47.2 billion and organic growth of 3% to 4% [4]. - Adjusted earnings for 2026 are anticipated to be between $24.22 and $24.80 per share, reflecting a 6% to 8% increase compared to the consensus of $24.61 [5]. - The pending acquisition of Clario, valued at $8.875 billion, could contribute an additional 20 to 25 cents to earnings per share in 2026 [5]. Market Reaction - Following the earnings report, Thermo Fisher Scientific shares experienced a decline of 3.20%, trading at $588.57 [5].

.@Mastercard, @honeywell, @thermofisher and @comcast reported their Q4 2025 earnings this morning.Here is what happened 👇 ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - The company reported strong financial performance for 2025, with revenue growth of 4% to $44.56 billion and adjusted EPS growth of 5% to $22.87 per share, reflecting effective management and operational excellence [5][22][30] - The company is well-positioned for 2026, initiating revenue guidance of $46.3 billion to $47.2 billion, representing 4% to 6% growth, and adjusted EPS guidance of $24.22 to $24.80, indicating 6% to 8% growth [22][40][43] Financial Performance - Q4 revenue grew 7% year over year to $12.21 billion, with adjusted operating income increasing 6% to $2.88 billion and adjusted EPS rising 8% to $6.57 per share [5][27] - For the full year, adjusted operating margin was 22.7%, with total adjusted operating income of $10.11 billion [5][29] - The company experienced a 3% organic growth in Q4, with a 2% contribution from acquisitions and a 2% tailwind from foreign exchange [28][30] Market Performance - In the pharma and biotech sector, Q4 growth was high single digits, driven by strong performance in bioproduction and research channels, while full-year growth was mid-single digits [6][8] - The academic and government market saw low single-digit declines, impacted by macro conditions in the US and China [7] - Diagnostics and healthcare delivered low single-digit growth in Q4, with flat growth for the full year [8] Growth Strategy - The company's growth strategy is based on three pillars: high-impact innovation, trusted partner status with customers, and a strong commercial engine [8][12] - Significant innovations in 2025 included the launch of high-impact products in chromatography, mass spectrometry, and bioproduction, enhancing the company's competitive position [9][10][11] Capital Deployment - In 2025, the company deployed approximately $16.5 billion, including $13 billion for mergers and acquisitions and $3.6 billion returned to shareholders through stock buybacks and dividends [15][34] - Key acquisitions included the filtration and separation business from Solventa and a sterile fill-finish site from Sanofi, enhancing the company's capabilities [16][34] Operational Excellence - The PPI business system played a critical role in managing costs and driving operational excellence, contributing to strong earnings growth [19][30] - The company plans to integrate artificial intelligence into its PPI system to further enhance operational efficiency [19] Corporate Social Responsibility - The company increased the use of renewable energy and expanded zero waste certification across its operations, aligning with long-term sustainability commitments [20] - Efforts to expand access to STEM and advance global health equity were highlighted as part of the company's mission-driven culture [20]

Core Insights - Thermo Fisher Scientific Inc. (TMO) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $6.57, exceeding the Zacks Consensus Estimate by 2.1% and reflecting a year-over-year increase of 7.7% [1][9] - The company's full-year adjusted EPS reached $22.87, surpassing the Zacks Consensus Estimate by 0.6% and showing a 4.6% year-over-year growth [2] Revenue Performance - TMO's revenues for the fourth quarter increased by 7.1% year over year to $12.22 billion, exceeding the Zacks Consensus Estimate by 2.3% [3][9] - For the full year, revenues rose 3.9% year over year to $44.56 billion, also surpassing the Zacks Consensus Estimate by 0.6% [3] Segment Analysis - Life Sciences Solutions segment revenues (24.1% of total revenues) grew by 13.5% year over year to $2.95 billion [4] - Analytical Instruments segment revenues (18.1%) increased by 1.4% year over year to $2.22 billion [5] - Specialty Diagnostics segment revenues (10%) rose by 5.2% year over year to $1.22 billion [6] - Laboratory Products and Biopharma Services segment revenues (52.2%) increased by 7.4% year over year to $6.38 billion [7] Margin and Cost Analysis - The gross margin for the fourth quarter was 41.5%, contracting by 150 basis points year over year due to a 10% rise in the cost of revenues [8] - Selling, general, and administrative expenses increased by 7.1% to $1.98 billion, while research and development expenses decreased by 4.5% year over year to $357 million [8] Financial Position - At the end of the fourth quarter, TMO had cash and cash equivalents and short-term investments totaling $10.11 billion, a significant increase from $3.55 billion at the end of the third quarter [10] - Cumulative net cash from operating activities at the end of the fourth quarter was $7.82 billion, down from $8.67 billion a year ago [10] Strategic Developments - TMO made several high-impact product launches in the fourth quarter, including the Helios MX1 Plasma Focused Ion Beam Scanning Electron Microscope, and received FDA approval for the Ion Torrent Oncomine Dx Target Test and the EXENT System, which are expected to support future growth [12][13]

Financial Performance - Revenue for Q4 2025 grew 7% year-over-year to $12.21 billion, while full-year revenue increased 4% to $44.56 billion [7][8] - Adjusted operating income for Q4 rose 6% to $2.88 billion, and for the full year, it grew 4% to $10.11 billion [8][27] - Adjusted EPS for Q4 increased 8% to $6.57, and for the full year, it grew 5% to $22.87 [8][26] - Adjusted operating margin for Q4 was 23.6%, and for the full year, it was 22.7% [8][28] Business Segment Performance - Life Science Solutions reported revenue growth of 13% in Q4 and 8% for the full year, driven by strong bioproduction performance [32] - Analytical Instruments saw a 1% increase in revenue for both Q4 and the full year, with adjusted operating income decreasing 12% in Q4 [33] - Specialty Diagnostics reported a 5% revenue increase in Q4 and a 4% increase for the full year, with adjusted operating income up 19% in Q4 [34] - Laboratory Products and Biopharma Services experienced a 7% revenue increase in Q4 and a 4% increase for the full year [35] Market Performance - North America and Asia Pacific grew low single digits in Q4, while Europe grew mid-single digits [27] - China experienced a low single-digit decline for both Q4 and the full year [27] Company Strategy and Competitive Position - The company’s growth strategy focuses on high-impact innovation, trusted partnerships, and a strong commercial engine [10][11] - Significant advancements in innovation were highlighted, including new product launches in chromatography, bioproduction, and clinical diagnostics [11][12][13] - Strategic partnerships, including collaborations with the Chan Zuckerberg Institute and OpenAI, were emphasized to enhance capabilities and productivity [16] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 from a position of strength, with expectations of continued share gain and operational excellence [6][24] - The guidance for 2026 includes revenue expectations of $46.3 billion to $47.2 billion, representing 4%-6% growth, and adjusted EPS guidance of $24.22 to $24.80, indicating 6%-8% growth [23][36] Other Important Information - The company deployed approximately $16.5 billion in 2025, including $13 billion for M&A and $3.6 billion returned to shareholders [17][30] - The acquisition of Clario, expected to close by mid-2026, is anticipated to be accretive to adjusted EPS by approximately $0.45 in the first year [19][38] Q&A Session Summary Question: Insights on the guidance and market conditions - Management indicated that the guidance assumes market conditions similar to 2025, with expectations of organic growth in the 3%-4% range [51][52] Question: Sentiment on biopharma spending - Management noted improved sentiment in biopharma spending, with indications of better budgets for 2026 [60][61] Question: Industry supply and demand dynamics in pharma services - Management highlighted strong demand in sterile fill finish and the strategic acquisition of a site to expand capacity [66][67] Question: Competitive dynamics in the channel business - Management stated that competitive dynamics remain stable, with a consistent share gain over the years [69][70] Question: Impact of ecosystem changes on customer preferences - Management discussed the positive impact of the Accelerator offering and collaboration with OpenAI to enhance drug development efficiency [78][79]

Financial Performance - In Q4 2025, revenue grew 7% year-over-year to $12.21 billion, and adjusted operating income increased 6% to $2.88 billion [5][20] - For the full year 2025, revenue grew 4% to $44.56 billion, with adjusted operating income also growing 4% to $10.11 billion [6][20] - Adjusted EPS for Q4 was $6.57, an 8% increase, while for the full year, it was $22.87, reflecting a 5% growth [6][20] Business Segment Performance - In the Life Sciences Solutions segment, Q4 revenue increased 13% year-over-year, driven by BioProduction, with full-year growth at 8% [28] - The Analytical Instruments segment saw Q4 revenue growth of 1%, with full-year revenue decreasing by 11% [29][30] - Specialty Diagnostics reported a 5% revenue increase in Q4 and a 4% increase for the full year, with adjusted operating income up 19% in Q4 [31] - The Laboratory Products and Biopharma Services segment experienced a 7% revenue increase in Q4 and a 4% increase for the full year [32] Market Performance - In Q4, North America and Asia Pacific grew low single digits, while Europe grew mid-single digits; China experienced a low single-digit decline [22] - For the full year, North America and Asia Pacific also grew low single digits, with China declining mid-single digits [23] Company Strategy and Competitive Position - The company’s growth strategy focuses on high-impact innovation, trusted partnerships, and a strong commercial engine [8][12] - In 2025, the company launched several high-impact products, including advancements in mass spectrometry and bioreactor technologies [9][10] - Strategic partnerships, including collaborations with the Chan Zuckerberg Institute and OpenAI, aim to enhance capabilities and improve productivity [12] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 from a position of strength, with a revenue guidance range of $46.3 billion to $47.2 billion, indicating 4%-6% growth [19][33] - The company anticipates organic growth of 3%-4% for 2026, with adjusted EPS guidance of $24.22-$24.80, reflecting 6%-8% growth [19][33] Other Important Information - The company deployed approximately $16.5 billion in 2025, including $13 billion for M&A and $3.6 billion returned to shareholders [13][26] - The acquisition of Clario, expected to close by mid-2026, is anticipated to be accretive to adjusted EPS by approximately $0.45 in the first year [15][27] Q&A Session Summary Question: Insights on 2026 guidance and market conditions - Management indicated that the guidance assumes similar market conditions to 2025, with expectations for gradual improvement in organic growth [45][47] Question: Sentiment in biopharma spending - Management noted positive sentiment in pharma and biotech, with expectations for improved spending plans in 2026 [53][56] Question: Industry supply and demand dynamics in Pharma Services - Management highlighted strong demand in sterile fill finish and the strategic acquisition of a New Jersey site to expand capacity [61][62] Question: Competitive advantage in the research and safety market - Management confirmed stable competitive dynamics and continued share gains in the research and safety market [64]

Financial Performance - In Q4 2025, revenue grew 7% year-over-year to $12.21 billion, while adjusted operating income increased 6% to $2.88 billion [5][25] - For the full year 2025, revenue grew 4% to $44.56 billion, and adjusted operating income also grew 4% to $10.11 billion [6][25] - Adjusted EPS for Q4 was $6.57, an 8% increase, and for the full year, it was $22.87, a 5% increase [6][25] Business Segment Performance - In the Life Science Solutions segment, Q4 revenue increased 13% year-over-year, with organic growth of 4%, driven by the bioproduction business [32] - The Analytical Instruments segment saw a 1% increase in revenue for both Q4 and the full year, with adjusted operating income decreasing 12% in Q4 due to tariffs and related FX impacts [33] - Specialty Diagnostics reported a 5% revenue growth in Q4, with adjusted operating income increasing 19% [34] - The Laboratory Products and Biopharma Services segment experienced a 7% revenue increase in Q4, with adjusted operating income rising 12% [35] Market Performance - In Q4, North America and Asia Pacific grew low single digits, while Europe grew mid single digits; China experienced a low single-digit decline [26] - For the full year, North America and Asia Pacific also grew low single digits, with China declining mid single digits [26] Company Strategy and Competitive Position - The company’s growth strategy focuses on high-impact innovation, trusted partnerships, and a strong commercial engine [10] - In 2025, the company launched several high-impact products, enhancing its competitive position and customer relevance [10][12] - Strategic partnerships, including collaborations with the Chan Zuckerberg Institute and OpenAI, aim to enhance productivity and innovation [14] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 from a position of strength, with a revenue guidance range of $46.3 billion to $47.2 billion, reflecting 4%-6% growth [22][37] - The company anticipates continued share gain momentum and strong earnings growth, with adjusted EPS guidance of $24.22 to $24.80, representing 6%-8% growth [22][37] Other Important Information - The company deployed approximately $16.5 billion in 2025, including $13 billion for M&A and $3.6 billion returned to shareholders [16][30] - The acquisition of Clario, expected to close by mid-2026, is anticipated to be accretive to adjusted EPS by approximately $0.45 in the first year [18][39] Q&A Session Summary Question: Can you discuss the acceleration in organic growth guidance for 2026? - Management indicated that the guidance assumes market conditions similar to 2025, with expectations for improved conditions leading to 3%-4% organic growth [49][50] Question: How are pharma budgets looking for 2026? - Management noted positive sentiment in pharma spending, with confidence in navigating government regulations and excitement around pipelines [58][60] Question: What is the outlook for the Pharma Services business? - The company is well-positioned in the Pharma Services sector, particularly in sterile fill finish, with heightened demand relative to industry capacity [66]

Core Viewpoint - Thermo Fisher Scientific reported strong quarterly earnings, exceeding expectations and showing growth compared to the previous year [1][2][3]. Financial Performance - The company achieved earnings of $6.57 per share, surpassing the Zacks Consensus Estimate of $6.43 per share, and up from $6.1 per share a year ago [1]. - Revenues for the quarter reached $12.22 billion, exceeding the Zacks Consensus Estimate by 2.28%, and up from $11.4 billion year-over-year [3]. Earnings Surprises - The earnings surprise for the latest quarter was +2.13%, following a previous surprise of +5.27% when actual earnings were $5.79 per share against an expectation of $5.5 per share [2]. Stock Performance - Thermo Fisher shares have increased approximately 4.9% since the beginning of the year, outperforming the S&P 500, which gained 1.9% [4]. Future Outlook - The company's earnings outlook is mixed, with current consensus EPS estimates of $5.57 for the upcoming quarter and $24.58 for the current fiscal year [8]. - The Zacks Rank for Thermo Fisher is currently 3 (Hold), indicating expected performance in line with the market [7]. Industry Context - The Medical - Instruments industry, to which Thermo Fisher belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable environment for performance [9].

Core Insights - Thermo Fisher Scientific exceeded Wall Street expectations for fourth-quarter profit and revenue, driven by strong demand for its tools and services utilized in drug development by pharmaceutical clients [1] Financial Performance - The company reported a significant increase in both profit and revenue for the fourth quarter, indicating robust performance in its core business segments [1]